Regulus Therapeutics Inc. has reportedly completed an underwritten public offering of 5.175 million shares of common stock, including 675,000 shares sold under the full exercise of an underwriters’ option to purchase additional shares. Gross proceeds from the offering were approximately $49.2 million. The LaJolla, California-based biopharmaceutical company develops medicines targeting microRNAs, among them RG-101 for the treatment of the Hepatitis C virus. It is also advancing its other microRNA therapeutics into clinical development in areas including oncology, fibrosis and metabolic diseases. See Regulus Therapeutics Inc. Press Release, July 23, 2013.